Astria Therapeuticsincis A Biopharmaceutical Company Focused On Discoveringdevelopingand Commercializing Therapies For Allergic And Immunological Diseasesfounded In 2008 And Rebranded In 2021The Company Is Headquartered In Bostonmassachusettsunder The Leadership Of Ceo Jill Milneastria Aims To Provide Life Changing Therapies That Prioritize Patient Centered Care And Innovation The Company S Product Pipeline Includes Navenibarta Monoclonal Antibody Inhibitor Of Plasma Kallikreinwhich Is In Phase 1B 2 Clinical Trials For Hereditary Angioedemaanother Key Development Is Star 0310A Monoclonal Antibody Ox40 Antagonist In Clinical Trials For Atopic Dermatitisastria Therapeutics Emphasizes The Importance Of Patient Stories And Experiences In Guiding Their Therapeutic Developmentreflecting Their Commitment To Understanding And Addressing Patient Needs
